secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001619856-24-000080
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q3 net loss $34.7M vs $10.0M YoY; cash $281M funds into H2 2026
-----------------------------------------------------------------------

- Revenue $2.0M, down from $23.7M due to AbbVie termination; R&D expense $30.4M.
- Cash & equivalents $281M as of Sept 30, 2024, down from $372.4M at Dec 31, 2023.
- CB-010 lupus GALLOP Phase 1 trial initiation expected by year-end 2024; Fast Track granted.
- CB-011 CaMMouflage dose escalation data for r/r MM expected H1 2025; no DLTs observed.
- Tina Albertson, MD/PhD, appointed CMO in August 2024; led BREYANZI development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000080/0001619856-24-000080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000080/crbu-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001619856-24-000080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer